New Mountain Capital to acquire Emmes from Behrman Capital for $800m.

New Mountain Capital, a growth-oriented investment firm, agreed to acquire Emmes, a global, tech-enabled full-service clinical research organization, from Behrman Capital, a private equity firm, for $800m. “Emmes is a world-class clinical research organization with a talented team, advancing life-saving therapeutics through leading clinical, data and technological capabilities. Our firm’s experience in the biopharma sector enables us to support the Emmes team in expanding and scaling the company in this next stage of growth," Kyle Peterson, New Mountain Managing Director.